29 August 2025
Jiangsu Hengrui Pharmaceuticals co ltd a pharmaceutical company known for its technological and scientific innovation, and IDEAYA Biosciences Inc., a global precision medicine oncology company, showcased its publication for highlighting its oral presentation on IDE849 (SHR-4849) at the IASLC 2025 World Conference on Lung Cancer, organized by the International Association for the Study of Lung Cancer (WCLC). The event will be held from September 6-9, 2025, in Barcelona, Spain. The presentation will show safety and efficacy results in SCLC from its phase 1 trial, which Hengrui hosted in China for IDE849 (SHR-4849). A commendable delta-like ligand 3 (DLL3)-focusing topoisomerase-1 (TOP1) payload antibody drug conjugate (ADC). The DLL3 has been intensified in various solid tumor types in which the unmet need remains the same, including melanoma, non-small cell lung cancer (NSCLC), SCLC, and neuroendocrine tumors (NETs).
IDEAYA will detail its poster presentation, including the data from its second published paper emphasizes merged pre-clinical synergy and mechanism data between IDE161 and TOP1 payload-based ADCs. It is a company’s proprietary, capable PARG inhibitor. This compilation holds the potential to improve the durability of TOP1 payload-related ADCs, also IDE034 and IDE849. The IDEAYA’s B7H3/PTK7 TOP1 ADC and the company’s alignment to the clinical development strategy of evaluation of rational combinations to work on enhancing and improving the clinical outcomes for cancer patients is a first priority.
Further, the oral presentation is titled ‘a first-in-human phase 1 study of SHR-4849 (IDE849), a DLL3-directed antibody drug conjugate (ADC) in relapsed SCLC.’ The presentation will be showcased on Sunday, 7th September, around 4:45-6:00 PM (CET), in session OA6-Novel ADCs in SCLC. The poster presentation (2165) is titled ‘dual PARG-TOP1 Inhibition exacerbates DNA protein crosslinks and replication stress; A promising strategy for enhancing TOP1i-ADC efficacy’. The presenter is Reeja Maskey, PHD. The presentation will be held on Monday, 8th September, around 10:30 am- 12:00 pm (CET) in session P2.10 Metastatic non-small cell lung cancer, antibody drug conjugate and cytotoxic therapy.
The poster and oral presentation will be available at https://ir.ideayabio.com/events
Chief medical officer at IDEAYA Biosciences, MD, PHD, Dr. Darrin Beaupre said, “We are proud of our partner Hengrui’s first-in-human phase 1 clinical safety and efficacy data presentation for IDE849 (SHR-4849) in SCLC patients at the WCLC 2025, as our company has advanced the worldwide development of IDE849.”
29 August 2025
29 August 2025
29 August 2025
29 August 2025